Durable Mid-Term Outcomes and High Rates of Meaningful Improvement After Hip Arthroscopy With Concomitant Periacetabular Osteotomy

髋关节镜联合髋臼周围截骨术后,中期疗效持久,且有显著改善率高

阅读:2

Abstract

PURPOSE: To evaluate 5-year outcomes following combined hip arthroscopy and periacetabular osteotomy (PAO) for the treatment of acetabular dysplasia and intra-articular pathology, with a focus on the rates of achieving clinically meaningful outcome thresholds. METHODS: Minimum 5-year outcome data from a prospectively maintained database were queried to identify patients who underwent concomitant primary hip arthroscopy and PAO between October 2010 and July 2019. Patient-reported outcomes evaluated included the modified Harris Hip Score (mHHS), non-arthritic hip score (NAHS), hip outcome score sport-specific subscale (HOS-SSS), and international hip outcome tool 12 (iHOT12). Clinically meaningful thresholds were also assessed, including minimal clinically important difference (MCID), patient-acceptable symptom state (PASS), and substantial clinical benefit (SCB). RESULTS: A total of 32 hips were included in this study. All PROs demonstrated significant improvement from the preoperative baseline to the 5-year follow-up (P < .001). Clinical outcomes remained durable, with no significant decline observed between 2-year and 5-year follow-ups (mHHS P = 0.612; NAHS P = 0.701; iHOT-12 P = 0.284; HOS-SSS P = 0.158). Similarly, achievement rates for MCID, PASS, and SCB thresholds were sustained over time (P = 0.105 to >0.999). Two hips (5.7%) converted to total hip arthroplasty (THA). CONCLUSIONS: Concomitant hip arthroscopy and PAO are an effective procedure with durable 5-year outcomes. Patients demonstrated sustained improvements and a high rate of clinically meaningful success, supporting the value of this combined approach in appropriately selected cases. LEVEL OF EVIDENCE: Level IV: Retrospective therapeutic case series.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。